Phase I study of AR-42 and decitabine in acute myeloid leukemia
| العنوان: | Phase I study of AR-42 and decitabine in acute myeloid leukemia |
|---|---|
| المؤلفون: | Mitch A. Phelps, William Blum, Sophia G. Liva, Rebecca B. Klisovic, Bhavana Bhatnagar, Christopher C. Coss, Jiang Wang, Guido Marcucci, Susan Geyer, Katherine Walsh, Ramiro Garzon, Qiuhong Zhao, Alison Walker |
| المصدر: | Leuk Lymphoma |
| بيانات النشر: | Informa UK Limited, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Cancer Research, medicine.drug_class, Decitabine, Article, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, HDAC inhibitor, Humans, Chemistry, Histone deacetylase inhibitor, Myeloid leukemia, Hematology, Effective dose (pharmacology), Phase i study, Histone Deacetylase Inhibitors, Leukemia, Myeloid, Acute, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Azacitidine, Cancer research, 030215 immunology, medicine.drug |
| الوصف: | This phase I trial sought to determine a biologically safe and effective dose of AR-42, a novel histone deacetylase inhibitor, which would lead to a doubling of miR-29b prior to decitabine administration. Thirteen patients with previously untreated or relapsed/refractory AML were treated at 3 dose levels (DL): AR-42 20 mg qd on d1,3,5 in DL1, 40 mg qd on d1,3,5 in DL2 and 40 mg qd on d1,3,4,5 in DL3. Patients received decitabine 20 mg/m(2) on d6–15 of each induction cycle and 20 mg/m(2) on d6–10 of each maintenance cycle. One DLT of polymicrobial sepsis and multi-organ failure occurred at DL3. Two patients achieved a CRi and one patient achieved a CR for an ORR of 23.1%. The higher risk features of this patient population and the dosing schedule of AR-42 may have led to the observed clinical response and failure to meet the biologic endpoint. |
| تدمد: | 1029-2403 1042-8194 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a8c0b303d5b593a7d481e7ba3befdc4Test https://doi.org/10.1080/10428194.2020.1719095Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....4a8c0b303d5b593a7d481e7ba3befdc4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10292403 10428194 |
|---|